STIM - Neuronetics, Inc Stock Price, Fair Value and News

2.43USD+0.04 (+1.67%)Market Closed

Market Summary

USD2.43+0.04

Market Closed

1.67%

STIM Stock Price

View Fullscreen

STIM RSI Chart

STIM Valuation

Market Cap

72.0M

Price/Earnings (Trailing)

-2.61

Price/Sales (Trailing)

0.98

Price/Free Cashflow

-2.5

STIM Price/Sales (Trailing)

STIM Profitability

Operating Margin

83.00%

Return on Equity

-99.59%

Return on Assets

-26.53%

Free Cashflow Yield

-40.04%

STIM Fundamentals

STIM Revenue

Revenue (TTM)

73.2M

Rev. Growth (Yr)

12.08%

Rev. Growth (Qtr)

-14.26%

STIM Earnings

Earnings (TTM)

-27.5M

Earnings Growth (Yr)

25.16%

Earnings Growth (Qtr)

-46.42%

Breaking Down STIM Revenue

Last 7 days

-5.9%

Last 30 days

-42.3%

Last 90 days

-23.8%

Trailing 12 Months

-11.1%

How does STIM drawdown profile look like?

STIM Financial Health

Current Ratio

5.65

Debt/Equity

2.15

Debt/Cashflow

-0.48

STIM Investor Care

Shares Dilution (1Y)

5.25%

Diluted EPS (TTM)

-0.95

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	73.2M	0	0	0
2023	66.6M	67.8M	69.2M	71.3M
2022	57.2M	59.3M	62.0M	65.2M
2021	50.1M	54.5M	55.9M	55.3M
2020	61.4M	54.6M	51.0M	49.2M
2019	55.4M	58.7M	60.9M	62.7M
2018	43.1M	46.0M	49.2M	52.8M
2017	35.8M	37.3M	38.9M	40.4M
2016	0	0	0	34.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Neuronetics, Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 29, 2024	macan william andrew	sold	-17,716	2.94	-6,026	evp, gc, cco and cs
Feb 29, 2024	macan william andrew	acquired	-	-	15,000	evp, gc, cco and cs
Feb 29, 2024	furlong stephen	acquired	-	-	15,000	evp, cfo and treasurer
Feb 28, 2024	macan william andrew	sold	-70,711	3.16	-22,377	evp, gc, cco and cs
Feb 28, 2024	furlong stephen	sold	-12,592	3.16	-3,985	evp, cfo and treasurer
Feb 27, 2024	furlong stephen	sold	-70,835	3.33	-21,272	evp, cfo and treasurer
Feb 26, 2024	sullivan keith j	sold	-66,963	3.3	-20,292	president and ceo
Feb 23, 2024	sullivan keith j	sold	-67,022	3.23	-20,750	president and ceo
Feb 22, 2024	sullivan keith j	sold	-67,348	3.23	-20,851	president and ceo
Feb 20, 2024	sullivan keith j	sold	-70,915	2.96	-23,958	president and ceo

Which funds bought or sold STIM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Squarepoint Ops LLC	new	-	95,666	95,666	-%
May 15, 2024	MARSHALL WACE, LLP	added	51.85	620,310	1,035,960	-%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	new	-	221,469	221,469	0.01%
May 15, 2024	DAFNA Capital Management LLC	unchanged	-	583,514	1,493,290	0.34%
May 15, 2024	TWO SIGMA ADVISERS, LP	reduced	-0.78	92,956	240,856	-%
May 15, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-580	-	-%
May 15, 2024	BOOTHBAY FUND MANAGEMENT, LLC	added	781	718,153	771,467	0.01%
May 15, 2024	G2 Investment Partners Management LLC	added	796	2,915,870	3,128,430	0.83%
May 15, 2024	WOLVERINE TRADING, LLC	sold off	-100	-32,422	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	317,521	317,521	-%

Are Funds Buying or Selling STIM?

Are funds buying STIM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own STIM

No. of Funds

Unveiling Neuronetics, Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 01, 2024	divisadero street capital management, lp	5.2%	1,539,382	SC 13G
Feb 14, 2024	kent lake capital llc	3.9%	1,116,041	SC 13G/A
Feb 13, 2024	cannell capital llc	9.57%	2,769,268	SC 13G/A
Feb 13, 2024	archon capital management llc	8.77%	2,537,097	SC 13G/A
Sep 22, 2023	kent lake capital llc	5.5%	1,600,100	SC 13G
Sep 11, 2023	cannell capital llc	9.80%	2,828,655	SC 13G
Aug 23, 2023	archon capital management llc	9.97%	2,877,706	SC 13G/A
Aug 17, 2023	cannell capital llc	8.45%	2,440,536	SC 13D/A
Jun 09, 2023	cannell capital llc	9.97%	2,841,223	SC 13D/A
Mar 23, 2023	cannell capital llc	11.03%	3,127,819	SC 13D/A

Recent SEC filings of Neuronetics, Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
May 07, 2024	8-K	Current Report
Apr 11, 2024	DEF 14A	DEF 14A
Apr 11, 2024	DEFA14A	DEFA14A
Apr 01, 2024	SC 13G	Major Ownership Report
Mar 28, 2024	8-K	Current Report
Mar 25, 2024	8-K	Current Report
Mar 08, 2024	10-K	Annual Report
Mar 06, 2024	8-K	Current Report

Peers (Alternatives to Neuronetics, Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	195.0B	23.7B	9.86%	17.02%	44.3	8.22	-8.94%	-35.91%
IDXX	45.3B	3.7B	11.69%	11.54%	52.29	12.17	8.57%	23.94%
A	45.1B	6.7B	9.86%	21.98%	36.53	6.7	-2.81%	-6.58%
DGX	15.6B	9.3B	9.44%	7.83%	18.49	1.68	-3.29%	6.68%
NTRA	13.2B	1.2B	18.77%	110.57%	-36.09	10.91	39.26%	33.08%
MEDP	12.6B	2.0B	4.81%	96.15%	40.23	6.4	25.57%	21.62%
CRL	12.0B	4.1B	-1.40%	23.62%	27.31	2.91	0.49%	-11.59%
EXAS	9.8B	2.5B	-18.36%	-33.26%	-40.98	3.88	15.21%	53.51%
MID-CAP
GH	3.2B	603.7M	51.00%	-5.47%	-6.84	5.22	25.21%	30.68%
NEOG	2.9B	929.2M	10.82%	-20.25%	1.8K	3.1	28.93%	111.61%
SMALL-CAP
CDNA	769.8M	275.1M	80.00%	89.96%	-4.2	2.8	-13.93%	-126.97%
ACRS	84.1M	31.1M	-2.48%	-85.57%	-1.09	2.7	0.95%	19.75%
AWH	34.6M	9.2M	-17.70%	-32.28%	-2.35	3.78	11.85%	45.80%
APDN	2.9M	5.5M	730.56%	169.37%	-0.24	0.53	-68.52%	-141.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Neuronetics, Inc News

Latest updates

Neuronetics, Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-14.3%	17,417,000	20,314,000	17,884,000	17,610,000	15,540,000	18,198,000	16,498,000	16,329,000	14,181,000	15,022,000	13,799,000	14,203,000	12,288,000	15,579,000	12,448,000	9,741,000	11,476,000	17,356,000	16,000,000	16,572,000	12,728,000
Gross Profit	-17.0%	13,088,000	15,771,000	11,764,000	12,774,000	11,396,000	13,808,500	12,928,000	12,290,000	10,696,000	11,484,000	10,655,000	11,453,000	10,067,000	11,816,000	9,791,000	7,418,000	8,665,000	13,137,000	11,808,000	12,401,000	9,921,000
Operating Expenses	-1.2%	19,947,000	20,198,000	20,635,000	20,123,000	21,303,000	21,535,000	20,382,000	22,086,000	20,831,000	18,393,000	17,837,000	18,017,000	16,976,000	14,476,000	12,215,000	14,277,000	19,031,000	20,076,000	18,136,000	19,008,000	16,977,000
S&GA Expenses	-0.6%	11,641,000	11,716,000	12,141,000	11,559,000	11,902,000	12,005,000	11,643,000	13,685,000	12,649,000	10,315,500	9,827,000	9,042,000	8,561,000	7,635,000	6,053,000	8,151,000	10,723,000	11,516,000	10,362,000	11,523,000	9,592,000
R&D Expenses	6.5%	2,349,000	2,206,500	2,155,000	2,364,000	2,790,000	3,139,500	2,348,000	2,045,000	1,803,000	1,743,500	1,575,000	2,294,000	2,311,000	2,112,000	1,952,000	2,116,000	3,021,000	4,248,000	3,489,000	3,224,000	2,786,000
EBITDA Margin	-	-	-	-	-	-	-	-	-	-	-	-0.43	-0.44	-0.48	-0.48	-0.46	-0.43	-0.38	-0.39	-0.32	-0.33	-0.35
Interest Expenses	-0.9%	1,826,000	1,843,500	1,184,000	1,144,000	1,253,000	1,212,000	1,061,000	1,000,000	978,000	1,064,000	993,000	977,000	985,000	1,011,000	1,002,000	986,000	1,523,000	905,000	930,000	931,000	919,000
EBT Margin	-	-	-	-	-	-	-	-	-	-	-	-0.52	-0.53	-0.58	-0.59	-0.57	-0.53	-0.47	-0.46	-0.40	-0.41	-0.44
Net Income	-46.4%	-7,873,000	-5,377,000	-9,391,000	-4,901,000	-10,520,000	-8,290,000	-7,609,000	-10,422,000	-10,838,000	-7,636,000	-8,151,000	-7,525,000	-7,881,000	-3,657,000	-3,418,000	-7,765,000	-12,613,000	-7,554,000	-6,867,000	-7,094,000	-7,529,000
Net Income Margin	11.1%	-0.38	-0.42	-0.48	-0.46	-0.55	-0.57	-0.59	-0.62	-0.60	-0.56	-0.49	-0.41	-	-	-	-	-	-	-	-	-
Free Cashflow	-655.0%	-12,000,000	2,162,000	-10,200,000	-8,787,000	-15,213,000	-3,100,000	-6,507,000	-8,950,000	-12,182,000	-4,541,000	-8,519,000	-5,772,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-10.4%	104	116	93.00	100	104	117	119	123	130	141	143	148	152	79.00	78.00	80.00	88.00	100	105	109	113
Current Assets	-12.7%	82.00	94.00	71.00	78.00	81.00	99.00	101	95.00	103	115	119	135	139	65.00	65.00	67.00	76.00	88.00	96.00	101	106
Cash Equivalents	-20.0%	48.00	60.00	36.00	46.00	55.00	70.00	74.00	71.00	81.00	94.00	99.00	116	121	49.00	51.00	54.00	64.00	76.00	82.00	90.00	96.00
Inventory	-17.3%	7.00	8.00	10.00	9.00	9.00	9.00	9.00	7.00	8.00	7.00	5.00	5.00	5.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	2.00
Net PPE	-8.1%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-6.7%	76.00	82.00	55.00	55.00	55.00	60.00	56.00	55.00	53.00	56.00	52.00	51.00	50.00	53.00	51.00	51.00	52.00	52.00	51.00	50.00	48.00
Current Liabilities	-26.8%	14.00	20.00	15.00	15.00	15.00	33.00	25.00	19.00	13.00	16.00	48.00	12.00	11.00	14.00	46.00	45.00	12.00	28.00	22.00	17.00	12.00
Long Term Debt	0.3%	59.00	59.00	37.00	37.00	37.00	23.00	27.00	31.00	35.00	35.00	-	35.00	35.00	35.00	-	-	34.00	20.00	23.00	27.00	31.00
LT Debt, Current	-	-	-	-	-	-	13.00	9.00	4.00	-	-	35.00	-	-	-	35.00	34.00	-	11.00	8.00	4.00	-
LT Debt, Non Current	-100.0%	-	59.00	37.00	37.00	37.00	23.00	27.00	31.00	35.00	35.00	-	35.00	35.00	35.00	-	-	34.00	20.00	23.00	27.00	31.00
Shareholder's Equity	-19.1%	28.00	34.00	38.00	45.00	48.00	57.00	63.00	68.00	77.00	85.00	91.00	97.00	102	25.00	27.00	29.00	37.00	48.00	54.00	60.00	65.00
Retained Earnings	-2.1%	-384	-376	-370	-361	-356	-345	-337	-329	-319	-308	-301	-292	-285	-277	-273	-270	-262	-250	-242	-235	-228
Additional Paid-In Capital	0.3%	411	410	408	407	404	403	400	398	396	394	392	390	387	303	301	300	299	298	297	295	294
Shares Outstanding	3.0%	30.00	29.00	29.00	29.00	28.00	27.00	27.00	27.00	27.00	25.00	25.00	26.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	57.00	-	-	-	68.00	-	-	-	396	-	-	-	33.00	-	-	-	226	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-655.0%	-12,000	2,162	-10,200	-8,787	-15,213	-3,100	-6,507	-8,950	-12,182	-4,541	-8,519	-5,772	-9,168	-1,713	-3,556	-9,481	-13,650	-6,403	-7,661	-6,848	-9,570
Share Based Compensation	-17.7%	1,338	1,626	1,855	2,033	1,805	2,113	2,178	2,203	2,252	1,703	1,961	2,009	2,196	1,516	1,046	646	1,196	976	935	1,022	501
Cashflow From Investing	112.1%	68.00	-563	66.00	-642	-183	-503	9,274	-966	-1,074	-801	-7,930	-433	-675	-115	-131	-218	-266	-359	-56.00	-124	-274
Cashflow From Financing	-100.0%	-	22,260	-	-62.00	499	245	-	10.00	-48.00	32.00	100	711	82,163	56.00	410	48.00	1,855	100	443	470	1,407

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

STIM Income Statement

2024-03-31

Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statements of Operations
Revenues	$ 17,417	$ 15,540
Cost of revenues	4,329	4,144
Gross profit	13,088	11,396
Operating expenses:
Sales and marketing	11,641	11,902
General and administrative	5,957	6,611
Research and development	2,349	2,790
Total operating expenses	19,947	21,303
Loss from operations	(6,859)	(9,907)
Other (income) expense:
Interest expense	1,826	1,253
Other income, net	(812)	(640)
Net loss	$ (7,873)	$ (10,520)
Net loss per share of common stock outstanding, basic	$ (0.27)	$ (0.38)
Net loss per share of common stock outstanding, diluted	$ (0.27)	$ (0.38)
Weighted-average common shares outstanding, basic	29,472	28,034
Weighted-average common shares outstanding, diluted	29,472	28,034

STIM Balance Sheet

2024-03-31

Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 47,730	$ 59,677
Accounts receivable, net	17,504	15,782
Inventory	6,694	8,093
Current portion of net investments in sales-type leases	816	905
Current portion of prepaid commission expense	2,630	2,514
Current portion of notes receivable	2,121	2,056
Prepaid expenses and other current assets	4,370	4,766
Total current assets	81,865	93,793
Property and equipment, net	1,847	2,009
Operating lease right-of-use assets	2,628	2,773
Net investments in sales-type leases	517	661
Prepaid commission expense	8,408	8,370
Long-term notes receivable	3,663	3,795
Other assets	4,883	4,430
Total assets	103,811	115,831
Current liabilities:
Accounts payable	2,979	4,752
Accrued expenses	9,045	12,595
Deferred revenue	1,623	1,620
Current portion of operating lease liabilities	851	845
Total current liabilities	14,498	19,812
Long-term debt, net	59,444	59,283
Deferred revenue	35	200
Operating lease liabilities	2,179	2,346
Total liabilities	76,156	81,641
Commitments and contingencies (Note 18)
Stockholders' equity:
Preferred stock, $0.01 par value: 10,000 shares authorized; no shares issued or outstanding on March 31, 2024 and December 31, 2023
Common stock, $0.01 par value: 200,000 shares authorized; 29,975 and 29,092 shares issued and outstanding on March 31, 2024 and December 31, 2023, respectively	300	291
Additional paid-in capital	411,309	409,980
Accumulated deficit	(383,954)	(376,081)
Total Stockholders' equity	27,655	34,190
Total Liabilities and Stockholders' equity	$ 103,811	$ 115,831

About Neuronetics, Inc

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

CEO	Mr. Keith J. Sullivan
WEBSITE	https://neurostar.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	209

Neuronetics, Inc Frequently Asked Questions

What is the ticker symbol for Neuronetics, Inc? What does STIM stand for in stocks?

STIM is the stock ticker symbol of Neuronetics, Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Neuronetics, Inc (STIM)?

As of Wed May 15 2024, market cap of Neuronetics, Inc is 71.99 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of STIM stock?

You can check STIM's fair value in chart for subscribers.

What is the fair value of STIM stock?

You can check STIM's fair value in chart for subscribers. The fair value of Neuronetics, Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Neuronetics, Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for STIM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Neuronetics, Inc a good stock to buy?

The fair value guage provides a quick view whether STIM is over valued or under valued. Whether Neuronetics, Inc is cheap or expensive depends on the assumptions which impact Neuronetics, Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for STIM.

What is Neuronetics, Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 15 2024, STIM's PE ratio (Price to Earnings) is -2.61 and Price to Sales (PS) ratio is 0.98. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. STIM PE ratio will change depending on the future growth rate expectations of investors.